Colorectal Neoplasms

Inclusion Criteria

- Male or female subjects >/= 18 years of age
 - Life expectancy of at least 3 months
 - Histological or cytological documentation of adenocarcinoma of the colon or rectum
 - Subjects with metastatic colorectal cancer (Stage IV)
 - Progression during or within 3 months following the last administration of approved standard therapies which must include fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab and cetuximab/panitumumab if KRAS WT (WT: wild-type i.e. no KRAS mutation)
 - Eastern Cooperative Oncology Group (ECOG) Performance Status of </= 1
 - Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements
 - Women of childbearing potential and men must agree to use adequate contraception since signing of the inform consent (IC) form until at least 3 months after the last study drug administration

Exclusion Criteria

- Prior treatment with regorafenib
 - Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study drug
 - Pregnant or breast-feeding subjects
 - Congestive heart failure >/= New York Heart Association (NYHA) class 2
 - Myocardial infarction less than 6 months before start of study drug
 - Ongoing infection > Grade 2 Common Terminology Criteria for Adverse Events (CTCAE) v. 4.0
 - Renal failure requiring hemo-or peritoneal dialysis